Immunofluorescence demonstration of tubulin and actin in estrogen-induced rat prolactinoma cells in vitro. Alteration of their distribution after bromocriptine, colchicine and cytochalasin B treatments.
Cultured cells in vitro from estrogen-induced rat prolactin-secreting adenomas (prolactinomas) were examined by indirect immunofluorescence microscopy for the distribution of cytoskeletal proteins and alterations of cytoskeleton after treatment with bromocriptine, colchicine and cytochalasin B (CB). After 8 days in culture, prolactinoma cells were well expanded and developed cytoplasmic processes were seen. The cytoplasmic microtubules were observed as fine reticular networks radiating from perinuclear portions toward the cell periphery when decorated with an antibody against tubulin. On the other hand, the actin filaments showed diffuse and spotty distribution when detected with an anti-actin antibody. Contaminated fibroblasts showed a reticular distribution of microtubules and a parallel array of actin cables which corresponds to "stress fibers" throughout the cytoplasm. After treatment with bromocriptine, the reticular distribution of microtubules in prolactinoma cells changed into a coarse and sparse pattern, which was identical with the changes in the distribution of tubulin after treatment with colchicine. On the other hand, distribution of actin was not affected by bromocriptine. Bromocriptine treatment did not alter the distribution of microtubules and actin filaments in fibroblasts, whereas colchicine changed the distribution of microtubules in both prolactinoma cells and fibroblasts. CB treatment changed the localization of actin filaments in both kinds of cells. These in vitro studies indicated bromocriptine would selectively affect the cytoplasmic microtubular system of prolactinoma cells.
D000199:Actins / Q000032:analysis*; D000236:Adenoma / Q000032:analysis* / Q000378:metabolism / Q000648:ultrastructure; D000818:Animals; D001971:Bromocriptine / Q000494:pharmacology; D002478:Cells, Cultured; D003078:Colchicine / Q000494:pharmacology; D003571:Cytochalasin B / Q000494:pharmacology; D004958:Estradiol; D005260:Female; D005455:Fluorescent Antibody Technique; D008868:Microtubule Proteins / Q000032:analysis*; D009363:Neoplasm Proteins / Q000032:analysis*; D010911:Pituitary Neoplasms / Q000032:analysis* / Q000378:metabolism / Q000648:ultrastructure; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D014404:Tubulin / Q000032:analysis*
D000199:Actins; D008868:Microtubule Proteins; D009363:Neoplasm Proteins; D014404:Tubulin; D001971:Bromocriptine; D003571:Cytochalasin B; D004958:Estradiol; D011388:Prolactin; D003078:Colchicine